Biological
Rilimogene galvacirepvec clinical trials
Also written PROSTVAC-V.
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 7
National Cancer Institute (NCI) (6) · Washington University School of Medicine (1) · Bavarian Nordic (1)
Often tested with
Tested in the same studies.
Rilimogene glafolivec (7) · Tricom (3) · Docetaxel (1) · Nivolumab (1) · Ipilimumab (1) · Vaccines, DNA (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1)
Studies
Open first, then newest update. How each study uses rilimogene galvacirepvec is read from its arms, and is right about nine times in ten.
Testing it · 8
- Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT02649855Written as PROSTVAC-V
- PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedPhase 2National Cancer Institute (NCI)NCT02326805Written as Rilimogene Galvacirepvec
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedPhase 1Washington University School of MedicineNCT03532217Written as PROSTVAC-V
- Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01875250Written as PROSTVAC-V (Vaccinia)/TRICOM
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerCompletedPhase 3Bavarian NordicNCT01322490Written as PROSTVAC-V
- Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00450463Written as PROSTVAC-V/TRICOM
- Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical ProstatectomyCompletedPhase 2National Cancer Institute (NCI)NCT02153918Written as PROSTVAC-V/TRICOM
- Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01145508Written as Rilimogene Galvacirepvec
Given in every arm · 1 — rilimogene galvacirepvec is usual care beside what is tested
Codes
What other systems call rilimogene galvacirepvec · ClinicalTrials.gg INT015048
- UNII (FDA) 59WJ3TGA5KRILIMOGENE GALVACIREPVECOne source FDA
- NCI Thesaurus C38681Rilimogene GalvacirepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 59WJ3TGA5K | RILIMOGENE GALVACIREPVEC | One source FDA |
| NCI Thesaurus | C38681 | Rilimogene Galvacirepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.